Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maraviroc Add-on Therapy for Steatohepatitis in HIV

Trial Profile

Maraviroc Add-on Therapy for Steatohepatitis in HIV

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms MASH
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
    • 04 Oct 2018 Status changed from active, no longer recruiting to recruiting.
    • 03 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top